Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514361 | 0.84 | GRM5 (0.41) | GRM5GPR119USP2SMN1; SMN2HDAC4 | |
| SCHEMBL513177 | 0.81 | HDAC4 (0.53) | GRM5GPR119SMN1; SMN2HDAC4SCD5 | |
| SCHEMBL513744 | 0.78 | GBA1 (0.51) | GRM5GPR119HDAC4 | |
| SCHEMBL513815 | 0.77 | GRM5 (0.47) | GRM5GPR119USP2SMN1; SMN2SCD5 | |
| SCHEMBL513325 | 0.76 | KCNH2 (0.49) | GRM5HDAC4KMT2A | |
| SCHEMBL21723194 | 0.75 | GRM5 (0.43) | GRM5GPR119USP2SMN1; SMN2RECQL | |
| SCHEMBL2899012 | 0.72 | GPR119 (0.53) | GPR119USP2SMN1; SMN2RECQLHPGD | |
| SCHEMBL24673913 | 0.72 | USP2 (0.51) | GRM5GPR119USP2SMN1; SMN2RECQL | |
| SCHEMBL10253506 | 0.72 | USP2 (0.51) | GRM5GPR119USP2SMN1; SMN2RECQL | |
| SCHEMBL24102957 | 0.72 | USP2 (0.49) | GRM5GPR119USP2SMN1; SMN2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477981-A1 | HETEROCYCLIC MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2012-07-25 | — | — | EP | disclosed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | GRM5 2/4885GPR119 674/4885USP2 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.